| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/06/2002 | CN1334726A Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists |
| 02/06/2002 | CN1334705A Fibre blend for enteral composition |
| 02/06/2002 | CN1334702A Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
| 02/06/2002 | CN1334336A Health-care wine |
| 02/06/2002 | CN1334123A Process for preparing freeze dried hepatitis A vaccine |
| 02/06/2002 | CN1334120A 'Futai'an' oral liquid |
| 02/06/2002 | CN1334119A Litholysizing bear gall powder |
| 02/06/2002 | CN1334117A Health-care food for treating dizziness and emesis |
| 02/06/2002 | CN1334116A Soft vinegar capsule |
| 02/06/2002 | CN1334108A 'Jiechanglikang' for treating colonopathy |
| 02/06/2002 | CN1078889C Non-pepitde tachykinin receptor antagonists |
| 02/05/2002 | US6344566 Method for producing enantiomer-free N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrolidine-1-yl)ethyl]-2,2-diphenylacetamide |
| 02/05/2002 | US6344563 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 02/05/2002 | US6344551 Contulakin-G, analogs thereof and uses therefor |
| 02/05/2002 | US6344486 Anticoagulants |
| 02/05/2002 | US6344470 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same |
| 02/05/2002 | US6344468 Substituted isoindolones and their use as cyclic GMP modulators in medicaments |
| 02/05/2002 | US6344466 Antithrombotic activity, use in inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, anticoagulants |
| 02/05/2002 | US6344452 Gastrin receptor antagonist, gastrointestinal disorders, etc |
| 02/05/2002 | US6344450 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/05/2002 | US6344441 Lipoprotein-regulating medicaments |
| 02/05/2002 | US6344440 Antisecretory factor peptides regulating pathological permeability changes |
| 02/05/2002 | US6344219 Oils of chenopodium ambrosiodes and adina pilulifera that inhibit pyloric spirillum |
| 02/05/2002 | US6344201 Inhibitors of e. coli and shigella enterotoxins; used for drugs and dna vaccines |
| 02/05/2002 | US6344196 Compositions and method for reducing gastro-intestinal distress due to alpha-d-galactoside-linked/containing sugars |
| 02/05/2002 | CA2242373C Teas for the amelioration of the effects of alcoholic drinks and processes for the production thereof |
| 02/05/2002 | CA2123403C Acyclic ethylenediamine derivatives as substance p receptor antagonists |
| 02/05/2002 | CA2078578C Medical use for tachykinin antagonists |
| 02/05/2002 | CA2019749C [.alpha.-(tert.butyl aminomethyl)-3,4-dichlorobenzyl] thioacetamide, a procedure for its preparation and its uses |
| 02/01/2002 | CA2354342A1 Alkyl amino acid derivatives useful as pharmaceutical agents |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008268A2 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | WO2002008256A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008218A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008212A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008188A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | WO2002008187A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002007821A1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
| 01/31/2002 | WO2002007782A2 Diagnosis of liver disease |
| 01/31/2002 | WO2002007772A2 Improved oral dosage formulations |
| 01/31/2002 | WO2002007771A1 Pharmaceutically active compound |
| 01/31/2002 | WO2002007741A1 Probiotic recolonisation therapy |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007692A1 Tooth whitening sets |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2002007533A2 Nutritional composition |
| 01/31/2002 | WO2002007531A1 Dietary lipids for improving skin and coat of pets |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001062280A3 Lipase-containing composition and methods of use thereof |
| 01/31/2002 | WO2001060832A3 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 01/31/2002 | WO2001057075A3 Virulence genes, proteins, and their use |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013352 Novel substituted diamine derivatives useful as motilin antagonists |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013320 Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/31/2002 | US20020013291 Reperfusion injury; 2-Deoxy-6-O-(2-deoxy-4-O-phosphono-3-O-(3-tetradecanoyloxytetradecanoyl)-2 -(3-octadecanoyloxy-tetradecanoylamino)-beta-D-glucopyranosyl)-2-(3 -hexadecanoyloxytetradecanoylamino)-D-glucopyranose |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013270 Administering a microbiocide to inhibit or eliminate at least one symptom of the disorder; also using a probiotic mixture including a replenishing gastrointestinal microbe; anxiolytic agents; autism; psychosis; attention deficit |
| 01/31/2002 | US20020013267 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012709 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012676 For inhibiting gastric acid secretion in mammals and man |
| 01/31/2002 | US20020012666 Administering to animal an egg product wherein the egg product is obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine |
| 01/31/2002 | US20020012661 Methods for introducing genes into mammalian subjects |
| 01/31/2002 | US20020012637 Administering to the oral cavity of a human or animal one or more lactic bacteria that are not part of resident microflora of mouth, that are low acidifying, and that are capable of adhering directly to pellicle of teeth |
| 01/31/2002 | DE10035227A1 Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2417097A1 Diagnosis of liver disease |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416647A1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
| 01/31/2002 | CA2416608A1 Pharmaceutically active compound |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415131A1 Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |